Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Initial data anticipated in the first half of 2025. - - Phase 1 study of CX-801 (interferon alpha-2b PROBODY® cytokine) as ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

the Akeso and Summit Therapeutics drug that bested Keytruda in a Phase 3 trial in lung cancer. Crescent’s drug, he claimed, is a “purpose-built molecule designed to recapitulate precisely the ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Keytruda is now under threat not only from ... the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Akeso shared data from its study, which indicated that ivonescimab ...